We are investigating whether semaglutide can help patients with schizophrenia and obesity improve their weight and metabolic health. This study compares semaglutide to a placebo to see its effects on various health measures.
Health conditions and diseases that the clinical trial is designed to study and treat.
Metabolic control in antipsychotic-using patients refers to the management of metabolic changes that can occur as a side effect of antipsychotic medications, which may lead to weight gain, diabetes, and other metabolic issues.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.